Celltrion announced on April 11 that “Zymfentra” (the U.S. brand name for Remsima), the world’s first subcutaneous formulation of infliximab for the treatment of autoimmune diseases developed in-house, has completed its formulation patent registration with the United States Patent and Trademark Offi
GC Cell, a fully integrated cell therapy pioneer, has announced poster presentations from studies of its preclinical study of GL205 (GCC2005), a CD5 CAR-NK targeting malignant T-cell lymphoma, and real-world data for the anticancer immunotherapy drug ‘Immuncell-LC’ at the AACR Annual Meeting 2024 th
Bereum, a pioneering force in postbiotic, has recently inked a strategic collaboration with Hyundai Corporation Group to venture into the North American market. The contract, valued at $10 million, marks a significant milestone in the company's journey, positioning it as the sole domestic competitor
SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced today Prof. Jan Holmgren of Sweden, and Profs. Barney Graham and Jason McLellan of the United States as the winners of the 2024 International Vaccine Institute-SK Bio
SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced today that the company broke ground on a major expansion of its vaccine manufacturing plant, L HOUSE, located in Andong, Gyeongsangbuk-do, South. The groundbreaking c
Samsung Bioepis announced on Feb. 25 that it has obtained a positive opinion for the sale of its biosimilar of Stelara, known as Pyzchiva, from the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA).The original drug of Pyzchiva developed by Janssen, know
Celltrion is expanding its market presence in Peru, a major Latin American country, by winning a series of successful public tenders.First of all, Truxima (rituximab) 500 mg won a tender held by the National Health Ministry of Peru (Centro Nacional de Abastecimiento de Recursos Estratégicos en Salud
The CEO Candidate Recommendation Committee of POSCO Holdings finally chose former POSCO President Jang In-hwa, a long-time POSCO insider, with rich experience in the steel business.POSCO Holdings held an extraordinary board meeting on Feb. 8 and resolved to select former POSCO President Jang In-hwa
Celltrion announced on Feb. 6 that Rani Therapeutics (Rani) in the United States has confirmed positive topline results in the Phase 1 clinical trial of oral ustekinumab (development name: RT-111). RT-111 is an oral formulation of Celltrion’s Stelara biosimilar, CT-P43, currently under development.I
Celltrion announced on Jan. 29 that it has completed its application to the U.S. Food and Drug Administration (FDA) for the approval of CT-P47, a biosimilar to the autoimmune disease treatment drug Actemra (ingredient name: tocilizumab). The application was based on the results of a global Phase 3 c
Celltrion has launched an 80-mg dosage form of its biosimilar Yuflyma (adalimumab) for the treatment of autoimmune diseases in the United States.Celltrion said on Jan. 17 that 80 mg is the same high-concentration (100 mg/ml) formulation as the 40 mg version that became available in the United States
Celltrion’s biosimilar products for the treatment of autoimmune diseases have successively won bids in major European countries.According to Celltrion on Jan. 12, Yuflyma (active ingredient: adalimumab) has successfully won a government bid in Italy. Yuflyma was awarded in the adalimumab government
Celltrion revealed on Dec. 26 that its biosimilar for autoimmune diseases, Yuflyma (CT-P17), has demonstrated equivalence and safety compared to the original drug, Humira.Developed by the American company AbbVie, Humira recorded sales of approximately US$21 brillion last year, making it the world’s
Dong-A Socio Group’s specialty drug affiliate, Dong-A ST, will enter the ADC market through the acquisition of an antibody-drug conjugate (ADC) linker platform company. ADCs are a treatment that combines an antibody that combines a target antigen with a cytotoxic drug as a linker and is known for it
Celltrion announced on Dec. 18 that it has received approval from the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan for a Phase 1 clinical trial plan (IND) for CT-P55, a biosimilar of the psoriasis treatment Cosentyx (active ingredient: secukinumab).CT-P55 is a new autoimmune disease bi
SK bioscience, an innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that the updated COVID-19 vaccine (NVX-CoV2601) developed by Novavax, a global company advancing protein-based vaccines with its Matrix-M adjuvant, has begun to be supplied
The author is an analyst for NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.Lundbeck has announced to first target TED and MS with APB-A1. The phase II study for TED should begin in 3Q24. Showing confidence in the CD40L pipeline, the firm sees superiority to IGF-1R inhibitor
bereum, a company specializing in postbiotics research for over 30 years, led by CEO Han Kwon-il, proudly announced that their meticulously crafted feminine beauty care brand, Young Clair Foam Wash, has secured the 1st place in the Feminine Care category at the 2023 Hwahae Beauty Awards.Young Clair
SK bioscience, an innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that the updated COVID-19 vaccine (NVX-CoV2601) developed by Novavax, a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, has received an emergen